Liposomal nanocarriers containing siRNA as small molecule-based drugs to overcome cancer drug resistance.
Mohsen SafaeiFatemeh KhalighiFatemeh Akhavan BehabadiZahra AbpeikarArash GoodarziSeyed Amin KouhpayehSohrab NajafipourVahid RamezaniPublished in: Nanomedicine (London, England) (2023)
This review discusses the application of nanoliposomes containing siRNA/drug to overcome multidrug resistance for all types of cancer treatments. As drug resistance-associated factors are overexpressed in many cancer cell types, pumping chemotherapy drugs out of the cytoplasm leads to an inadequate therapeutic response. The siRNA/drug-loaded nanoliposomes are a promising approach to treating multidrug-resistant cancer, as they can effectively transmit a small-molecule drug into the target cytoplasm, ensuring that the drug binds efficiently. Moreover, nanoliposome-based therapeutics with advances in nanotechnology can effectively deliver siRNA to cancer cells. Overall, nanoliposomes have the potential to effectively deliver siRNA and small-molecule drugs in a targeted manner and are thus a promising tool for the treatment of cancer and other diseases.
Keyphrases